Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2007-04-19
2008-12-16
Navarro, Mark (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S423000, C514S406000, C604S511000, C604S531000
Reexamination Certificate
active
07465458
ABSTRACT:
The present invention provides methods of treating an eye disorder. The methods comprise a step of locally administering aClostridialtoxin to the eye of a patient to treat the disorder. The eye disorder may be associated with an inflammation of the eye, including for example, bacterial conjunctivitis, fungal conjunctivitis, viral conjunctivitis, uveitis, keratic precipitates, macular edema, and inflammation response after intra-ocular lens implantation. TheClostridialtoxin may be produced by aClostridial beratti, aClostridia butyricum, aClostridial tetanibacterium and/or aClostridial botulinum.
REFERENCES:
patent: 5250293 (1993-10-01), Gleich
patent: 5401243 (1995-03-01), Borodic
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5616122 (1997-04-01), Lam et al.
patent: 5670484 (1997-09-01), Binder
patent: 5714468 (1998-02-01), Binder
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6063768 (2000-05-01), First
patent: 6113915 (2000-09-01), Aoki et al.
patent: 6139845 (2000-10-01), Donovan
patent: 6143306 (2000-11-01), Donovan
patent: 6265379 (2001-07-01), Donovan
patent: 6299893 (2001-10-01), Schwartz et al.
patent: 6306403 (2001-10-01), Donovan
patent: 6306423 (2001-10-01), Donovan et al.
patent: 6312708 (2001-11-01), Donovan
patent: 6328977 (2001-12-01), Donovan
patent: 6358513 (2002-03-01), Voet et al.
patent: 6358926 (2002-03-01), Donovan
patent: 6365164 (2002-04-01), Schmidt
patent: 6383509 (2002-05-01), Donovan
patent: 6395277 (2002-05-01), Graham
patent: 6423319 (2002-07-01), Brooks et al.
patent: 6429189 (2002-08-01), Borodic
patent: 6440964 (2002-08-01), Cagle et al.
patent: 6458365 (2002-10-01), Aoki et al.
patent: 6464986 (2002-10-01), Aoki et al.
patent: 6585993 (2003-07-01), Donovan et al.
patent: 6692481 (2004-02-01), Guerrero
patent: 6743424 (2004-06-01), Donovan
patent: 7211261 (2007-05-01), Moyer et al.
patent: 7220422 (2007-05-01), First
patent: 7390496 (2008-06-01), Ackerman
patent: 7393537 (2008-07-01), Ackerman
patent: 2002/0064536 (2002-05-01), Hunt
patent: 2002/0192239 (2002-12-01), Borodic
patent: 2003/0092640 (2003-05-01), Boettner
patent: 2003/0114830 (2003-06-01), Guerrero
patent: 2004/0058313 (2004-03-01), Abreu
patent: 2004/0122254 (2004-06-01), Fujimoto et al.
patent: 2004/0170665 (2004-09-01), Donovan
patent: 2004/0204471 (2004-10-01), Seibert
patent: 2004/0213811 (2004-10-01), Ackerman
patent: 2004/0220100 (2004-11-01), Waugh
patent: 2004/0265935 (2004-12-01), Atassi
patent: 2005/0025778 (2005-02-01), Cormier et al.
patent: 2005/0043410 (2005-02-01), Brazzell et al.
patent: 2006/0067950 (2006-03-01), Taylor
patent: 2006/0106104 (2006-05-01), Vehige
patent: 2006/0182767 (2006-08-01), Borodic
patent: 2006/0182783 (2006-08-01), Hughes et al.
patent: 2006/0211752 (2006-09-01), Kohn
patent: 2007/0059336 (2007-03-01), Hughes et al.
patent: 1 147 776 (2001-10-01), None
patent: WO01/01959 (2001-01-01), None
Bigalke, H. et al.; Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture;Brain Research; 360; 318-324; 1985.
Bigalke, H. et al.;Tetanus Toxin and Botulinum A Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations from Rat Brain and Spinal Cord;Naunyn-Schmiedeberg's Arch Pharmacol; 316; 244-251, 1981.
Binz, T. et al.;The Complete Sequence of Botulinum Neurotoxin Type A and Comparison with other Clostridial Neurotoxins; J Biological Chemistry265 (16); 9153-9158; 1990.
Cohen, D.A.,et al.,Botulinum injection therapy for blepharospasm: a review and report of 75 patients, Clinical Neuropharmacology, vol. 9, No. 5, pp. 415-429 1986 Raven Press, NY.
Denniston, A et al., Hop. Med, Aug. 2001, vol. 62(6), pp. 477-479.
Duggan, Michael J. et al.,A survey of botulinum neurotoxin substrate expression in cells;Mov Disord; May 1995; 10(3) p. 376.
Ellis, MF et al.,An evealuation of the safety and efficacy of botulinum toxin type A(BOTOX)when used to produce a protective ptosis, Clin and Exper Ophthalmology, Dec. 2001, vol. 29(6), pp. 394-399.
Ferrari et al.;The protein disulphide-isomerase family: unraveling a string of folds; Journal Biochem (1999) 339; 1-10.
Habermann, E. et al.;Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release From Cultured Mouse Brain;J. Neurochem; 51(2) 522-527; 1988.
Habermann, E.; Inhibition by Tetanus and Botulinum A Toxin of the release of [3H]GABA from Rat Brain Homogenate;Experientia; 44; 224-226; 1988.
Habermann; E.; I-Labeled Neurotoxin from Clostridium Botulinum A: Preparation, Binding to Synaptosomes and Ascent to the Spinal Cord;Naunyn-Schmiedeberg's Arch. Pharmacol; 281; 1974; 47-56.
Horwath-Winter et al.;The Effect of Botulinum Toxin A Treatment on Tear Function Parameters and on the Ocular Surface; Adv Exp Med Biol; 2002; 506 (Pt B); 1241-6.
Jankovic, J. et al.;Therapy with Botulinum Toxin; Marcel Dekker, Inc., 1994; p. 5.
Marjama-Jyons, J. et al.;Tremor-Predominant Parkinson's Disease; Drug & Aging16(4); 273-278; 2000.
Moyer, E. et al.;Botulinum Toxin Type B: Experimental and Cllinical Experience, Chapter 6, pp. 71-85 ofTherapy With Botulinum Toxin, edited by Jankovic, J. et al. 1994, Marcel Dekker, Inc.
Naumann et al.;Botulinum toxin type A in the treatment of focal, axiallary and palmar hyperhidrosis and other hyperhidrotic conditions; European J. Neurology6 (Supp 4); S111-S1150; 1999.
Ophthalmology Times,World of Ophthalmology Converges Upon New Orleans, V23, No. 21, p. 40.
Pearce, L.B.;Pharmacologic Characterization of Botulinum Toxin for Basic Science and Medicine; Toxicon; 35(9) 1373-1412 at 1393.
Ragona et al.;Management of Parotid Sialocele with Botulinum Toxin; Laryngoscope109; 1344-1346; 1999.
Sanchez-Prieto, J. et al.;Botulinum Toxin A Blocks Glutamate Exocytosis from Guinea Pg Cerebral Cortical Synaptosomes; Eur J Biochem; 165; 675-681; 1987.
Schantz, E.J. et al.;Properties and use of Botulinum Toxin and other Microbial Neurotoxins in Medicine; Microbiol Rev; 56; 80-99; 1992.
Singh;Critical Aspects of BacterialProtein Toxins; pp. 63-84 Chapter 4 ofNatural Toxins II, edited by B.R. Singh et al., Plenum Press, New York 1976.
Sloop et al.;Reconstituted Botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use; Neurology; 48; 249-53; 1997.
Soylev, MF et al.,Anesthesia with EMLA cream for botulinum A toxin injection into eyelids, Ophthalmologica, vol. 216, 2002, pp. 356-358.
Tran et al.;Calcitonin Gene-Related Peptide Induces IL-8 Synthesis in Human Corneal Epithelial Cells; The Journal of Immunology; Apr. 15, 2000; 164(8); 4307-12.
Uddin, J.M.,Treatment of upper eyelid retraction associated with thyroid eye disease with subconjunctival botulinum toxin injection, Ophthalmology Jun. 2002, No. 6, vol. 109, pp. 1183-1187.
Weigand et al.; Naunyn-Schmiedeberg's Arch Pharmacol; 1976; 292, 161-165.
Allergan Inc.
Donovan Stephen
Nassif Claude L.
Navarro Mark
Portner Ginny
LandOfFree
Methods for treating eye disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating eye disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating eye disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4031283